Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
For Groups 1 to 4, the primary objective of this study is to estimate the clinical benefit of
cemiplimab monotherapy for patients with: metastatic (nodal or distant) cutaneous squamous
cell carcinoma (CSCC), or unresectable locally advanced CSCC. For Group 6, the primary
objective is to provide additional efficacy and safety data for cemiplimab monotherapy in
patients with advanced CSCC (metastatic [nodal or distant] or locally advanced. Clinical
benefit is measured by overall response rate (ORR) according to central review in each group.